PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
12.50%
Gross profit growth at 50-75% of AXSM's 18.30%. Martin Whitman would question if cost structure or brand is lagging.
-29.39%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-29.39%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-30.95%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-22.58%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-22.58%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
7.95%
Share count expansion well above AXSM's 0.38%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.95%
Diluted share count expanding well above AXSM's 0.38%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-8.11%
Negative OCF growth while AXSM is at 43.68%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-7.95%
Negative FCF growth while AXSM is at 43.69%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while AXSM stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
91.14%
Positive long-term OCF/share growth while AXSM is negative. John Neff would see a structural advantage in sustained cash generation.
75.06%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
-16.88%
Negative 3Y OCF/share CAGR while AXSM stands at 6.30%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-109.23%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
62.10%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
-51.96%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-71.08%
Negative equity/share CAGR over 10 years while AXSM stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-53.15%
Negative 5Y equity/share growth while AXSM is at 155.38%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-63.40%
Negative 3Y equity/share growth while AXSM is at 13.78%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.71%
Asset growth above 1.5x AXSM's 0.46%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-7.41%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-6.71%
We’re deleveraging while AXSM stands at 1.25%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
37.48%
R&D growth drastically higher vs. AXSM's 36.26%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
21.30%
SG&A growth well above AXSM's 4.63%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.